



Published in final edited form as:

Nat Genet. 2017 January ; 49(1): 36–45. doi:10.1038/ng.3720.

The Genomic Landscape of Balanced Cytogenetic Abnormalities Associated with Human Congenital Anomalies

A full list of authors and affiliations appears at the end of the article.

Abstract

Despite their clinical significance, characterization of balanced chromosomal abnormalities (BCAs) has largely been restricted to cytogenetic resolution. We explored the landscape of BCAs at nucleotide resolution in 273 subjects with a spectrum of congenital anomalies. Whole-genome sequencing revised 93% of karyotypes and revealed complexity that was cryptic to karyotyping in 21% of BCAs, highlighting the limitations of conventional cytogenetic approaches. At least 33.9% of BCAs resulted in gene disruption that likely contributed to the developmental phenotype, 5.2% were associated with pathogenic genomic imbalances, and 7.3% disrupted topologically associated domains (TADs) encompassing known syndromic loci. Remarkably, BCA breakpoints in eight subjects altered a single TAD encompassing *MEF2C*, a known driver of 5q14.3 microdeletion syndrome, resulting in decreased *MEF2C* expression. This study proposes that sequence-level resolution dramatically improves prediction of clinical outcomes for balanced rearrangements, and provides insight into novel pathogenic mechanisms such as altered regulation due to changes in chromosome topology.

Keywords

Cytogenetics; structural variation; balanced chromosomal abnormality; congenital anomaly; intellectual disability; autism; translocation; inversion; chromothripsis; topologically associated domain (TAD); Hi-C; *MEF2C*

*Correspondence should be addressed to M.E.T. (talkowski@chgr.mgh.harvard.edu).

AUTHOR CONTRIBUTIONS

M.E.T, J.F.G, C.C.M, E.T., J.C.H., W.P.K., N.dL. and H.G.B designed the study. C.R., H.B., R.L.C., V.P., I.B., C.C., J.T.G., M.R.S., M.J.vR. and W.P.K., performed computational analyses. C.H., C.M.S., R.A., M-A.An., C.A., E.C., B.B.C., J.K., W.L., P.M., L.M., T.M., D.P., J.R., M.J.W. and A.W. performed cellular, molecular or genomic experiments. T.K., E.M., J.C.H, M-A.Ab., O.A-A-R., E.A., S.L.A-E., F.S.A, Y.A., K.A-Y, J.F.A, T.B., J.A.B., E.B., E.M.H.F.B., E.H.B, C.W.B., H.T.B., B.C., K.C., H.C., T.C., D.D., M.A.D., A.D., M.D'H., B.B.A.dV., D.L.E., H.L.F., H.F., D.R.F., P.G., D.G., T.G., M.G., B.H.G., C.G., K.W.G., A.L.G., A.H-K., D.J.H., M.A.H., R.Hi., R.Ho., J.D.H., R.J.H., M.W.H., A.M.I., Mi.I., Me.I., J.C.J., S.J., T.J., J.P.J., M.C.J., S.G.K, D.A.K., P.M.K., Y.L., E.L., K.L., A.V.L., Ha.L., Ho.L., E.C.L., C.L., E.J.L., D.L., M.J.M., G.M., C.L.M., D.M.F, M.W.M., C.Z.M., B.M., S.M., L.R.M., E.M., S.M., T.M., M.E.M., G.M., A.N., Z.O., S.P, S.P.P, S.P, K.P, R.E.P.A., P.J.P., G.P., S.R., L.R., W.R., D.R., I.R., F.R., P.R., S.L.P.S., R.Sh., R.Sp., E.S., B.S., J.T., J.V.T, B.W.vB., J.vdK., I.vdB., T.vE., C.M.vR-A, S.V., C.M.L.V-T., D.P.W., S.W., M.C.A.Y., R.T.Z., B.L., H.G.B., N.dL., W.P.K., E.C.T. C.C.M, and J.F.G. ascertained and enrolled subjects and provided phenotypic information. C.R. and M.E.T. wrote the manuscript, which was approved by all authors.

COMPETING FINANCIAL INTERESTS

The authors have none to declare.

Data availability

All reported breakpoints and their clinical interpretation have been submitted to dbVar (accession number: nstd133) and ClinVar (accession numbers: SCV000320745 to SCV000320992).

Balanced chromosomal abnormalities (BCA) are a class of structural variation involving rearrangement of chromosome structure that alters the orientation or localization of a genomic segment without a concomitant large gain or loss of DNA. This class of variation includes inversions, translocations, excisions/insertions, and more complex rearrangements consisting of combinations of such events. Cytogenetic studies of unselected newborns and control adult males estimate a prevalence of 0.2–0.5% for BCAs in the general population^{1–3}. By contrast, an approximate five-fold increase in the prevalence of BCAs detected by karyotyping has been reported among subjects with neurodevelopmental disorders, particularly intellectual disability (1.5%)⁴ and autism spectrum disorder (ASD; 1.3%)⁵, suggesting that a meaningful fraction of BCAs may represent highly penetrant mutations in those subjects.

Delineating the breakpoints of BCAs, and the genomic regions that they disrupt, has long been a fertile area of novel gene discovery and has greatly contributed to the annotation of the morbid map of the human genome^{6–8}. Despite their significance in human disease, the clinical detection of this unique class of rearrangements still relies upon conventional cytogenetic methods such as karyotyping that are limited to microscopic resolution (~3–10 Mb)⁹. The absence of gross genomic imbalances renders BCAs invisible to higher resolution techniques that currently serve as first-tier diagnostic screens for many developmental anomalies of unknown etiology: chromosomal microarray (CMA), which can detect microscopic and sub-microscopic copy number variants (CNVs), or whole-exome sequencing (WES), which surveys single nucleotide variants within coding regions. We have recently shown that innovations in genomic technologies can efficiently reveal BCA breakpoints at nucleotide resolution with a cost and timeframe comparable to clinical CMA or karyotyping; however, only a limited number of BCAs have been evaluated to date^{7,10–15}

In this study, we explored several fundamental but previously intractable questions regarding *de novo* BCAs associated with human developmental anomalies, such as the origins of their formation, the genomic properties of the sequences that they disrupt, and the mechanisms by which they can act as dominant pathogenic mutations. We evaluated 273 subjects ascertained based upon the presence of a BCA discovered by karyotyping in a proband that presented with a developmental anomaly. We mapped these BCA breakpoints at basepair resolution and created a framework to interpret their significance based on convergent genomic datasets, including CNV and WES data in tens of thousands of individuals. We also integrated data from high-resolution maps of chromosomal compartmentalization in the nucleus to predict long-range regulatory effects^{16,17}, and confirm those predictions with functional validation. Our findings indicate that formation of BCAs involves a variety of mechanisms, that the end-result often reflects substantial complexity invisible to cytogenetic assessment, that BCAs directly disrupt genes likely to contribute to early developmental abnormalities in at least one-third of subjects, and that BCAs can cause long-range regulatory changes due to alterations to the chromosome structure.

RESULTS

Sequencing BCAs reveals cryptic complexity

We sequenced DNA from 273 subjects originating from five primary referral sites that collectively engaged over 100 clinical investigators. Subjects harbored a BCA that was detected by karyotyping and presented with varied congenital and/or developmental anomalies. Most subjects were surveyed using large-insert whole-genome sequencing (liWGS or ‘jumping libraries’; 83%), with the remainder of subjects being analyzed by standard short-insert WGS or targeted breakpoint sequencing (see **Online Methods**; Supplementary Table 1). Subjects were preferentially selected with confirmed *de novo* BCAs based on cytogenetic studies or with rearrangements that segregated with a phenotypic anomaly within a family (72.5% of subjects); however, inheritance information was unavailable for one or both parents in the remaining 27.5% of subjects. Subjects harboring BCAs that were inherited from an unaffected parent were excluded from this study. Of interest, 62.6% of subjects received clinical CMA screening prior to enrollment to confirm the absence of a pathogenic CNV (Table 1). Subjects presented with a spectrum of clinical features: congenital anomalies ranged from organ-specific disorders to multisystem abnormalities, as well as neurodevelopmental conditions such as intellectual disability or ASD (Table 1). While no specific phenotypes were prioritized for inclusion (Supplementary Fig. 1), neurological defects were the most common feature in the cohort (80.2% of subjects when using digitalized phenotypes from Human Phenome Ontology [HPO]¹⁸; Table 1; Supplementary Table 2).

Breakpoints were identified in 248 of the 273 subjects (90.8%); all subsequent analyses were restricted to these 248 subjects. This success rate was consistent with expectations, as simulation of one million breakpoints in the genome suggested that 7.6% of breakpoints were localized within genomic segments that cannot be confidently mapped by short-read sequencing (Supplementary Fig. 2). Sequencing identified 876 breakpoints genome-wide (Fig. 1a) and revised the breakpoint localization by at least one sub-band in 93% of subjects when compared to the karyotype interpretation (breakpoint positions provided in Supplementary Table 3). Across all rearrangements, 26% (n=65) of BCAs were found to be complex (*i.e.*, involved three or more breakpoints; Supplementary Fig. 3–65), including 5% (n=13) that were consistent with the phenomena of chromothripsis or chromoplexy (complex reorganization of the chromosomes involving extensive shattering and random ligation of fragments from one or more chromosomes)^{19–23}. The most complex BCA involved 57 breakpoints (Supplementary Fig. 59). When analyses were restricted to the 230 subjects for which the karyotype suggested a simple chromosomal exchange, 48 (21%) were determined to harbor complexity that was cryptic to the karyotype, emphasizing the insights that are gained from nucleotide resolution. Across all BCAs, 80.7% resolved to less than ten kilobases of total genomic imbalance, although several cases harbored large cryptic imbalances (mostly deletions) of varied impact (Fig. 1b; Supplementary Table 4). Importantly, only 12.2% had imbalances of >100 kb in this study (9.3% greater than 1 Mb), representing a significantly lower fraction than previous cytogenetic estimates²⁴. Genomic imbalances associated with BCAs were larger on average among subjects without CMA pre-screening, with 15.5% harboring imbalances >1 Mb versus 5.9% in subjects pre-screened by

CMA (Fig. 1b; Supplementary Table 4). The total genomic imbalance generally increased with the number of breakpoints, though there were chromothripsis and chromoplexy events that were essentially balanced (*e.g.*, subject NIJ19 involved 13 junctions across five chromosomes that resolved to a final genomic imbalance of only 631 bases).

BCA formation is mediated by multiple molecular mechanisms

Extensive mechanistic studies have been performed on breakpoints of large CNV datasets; however, the limited scale and resolution of BCA studies have precluded similar analyses for balanced rearrangements. Using precise junction sequences from 662 breakpoints, we found that nearly half displayed signatures of blunt-end ligation (45%), presumably driven by non-homologous end joining (NHEJ) (Fig. 1c). A substantial fraction (29%) involved microhomology of 2–15 bp at the breakpoint junction, indicating that template-switching coupled to DNA-replication mechanisms such as microhomology-mediated break-induced replication (MMBIR) contribute to a substantial fraction of BCAs²⁵. A comparable fraction (25%) of junctions harbored micro-insertions of several basepairs, consistent with NHEJ or fork stalling and template switching (FoSTeS) mechanisms (Fig. 1c). Only nine junctions (1%) contained long stretches of homologous sequences (>100 bp) that would be consistent with homology-mediated repair. This is certainly an underestimate given the limitations of short-read sequencing to capture rearrangements localized within highly homologous sequences such as segmental duplications or microsatellites. BCA breakpoint signatures from this study were also compared to 8,943 deletion breakpoints identified in 1,092 samples from the 1000 Genomes Project²⁶, revealing that BCA breakpoints were enriched for blunt-end signatures while depleted for microhomology and large homology sequences compared to deletion breakpoints (Supplementary Fig. 66).

Comparison of the observed breakpoints to 100,000 sets of simulated breakpoints that retained the properties of the observed dataset (see **Online Methods**) established nominal enrichment for repeat elements ($P=0.021$) and fragile sites ($P=0.043$), while no significant enrichment for the other genomic features tested (Supplementary Fig. 67). Incorporating Hi-C interaction data to explore the association between nuclear organization of the chromosomes and BCA formation revealed that pairs of loci comprising a BCA breakpoint did not stem from regions with significantly higher contact patterns in the nucleus¹⁷; however, these pairs displayed genome-wide interaction patterns that were more correlated than random pairings ($P=0.046$; Supplementary Note and Supplementary Fig. 68). These results suggest that DNA fragments involved in BCA formation are more likely to be co-localized in the same or neighboring sub-compartments prior to chromosomal reassembly, though at the sample sizes available they did not necessarily harbor increased direct interactions.

BCA breakpoints associated with congenital anomalies are enriched for functionally relevant loci

While protein-coding sequences represent less than 2% of the human genome, the total genic space in which a structural variation can disrupt a transcript is considerable as the cumulative coverage of transcribed regions is over 60% from recent annotations²⁷. Consistent with this expectation, 67% (589/876) of breakpoints in this study disrupted a

gene, and at least one gene was truncated in most BCAs (75%, 186/248), which did not deviate from random expectations (observed $n=408$ genes, expected $n=392\pm 20$, $P=0.220$; Supplementary Fig. 69). The properties of the disrupted genes, however, deviated significantly from randomly breakpoints for several key features, suggesting that the pathogenic impact of BCAs in this cohort is not a consequence of their likelihood to disrupt genes but rather a reflection of the gene(s) that they alter (disrupted genes provided in Supplementary Table 5).

We observed significant enrichment for disruption of genes highly intolerant to truncating mutations, as defined by two independent groups ($P=0.027$ for Petrovski *et al.*, $P=0.0009$ for Samocha *et al.*; Fig. 2a)^{28,29}, embryonically expressed genes ($P=0.001$)³⁰, and genes previously associated with autosomal dominant disorders ($P=0.002$)³¹, whereas no enrichment was observed for genes associated with autosomal recessive disorders ($P=0.294$; Fig. 2a)³¹. The strongest enrichment at breakpoints was detected for genes previously associated with developmental disorders (2 *de novo* LoF mutations [dnLoF]) as amalgamated from independent datasets ($P=2\times 10^{-5}$; Supplementary Table 6). Significant enrichment was also observed at breakpoints for FMRP-target genes and chromatin remodeling genes^{32,33}, consistent with the association of genes implicated in neurodevelopmental disorders (Fig. 2b)^{7,30,34–37}, but not *CHD8* target genes^{38,39}. When further incorporating expression data of the developing brain from BrainSpan⁴⁰, truncated genes showed higher expression patterns during early developmental stages than randomly simulated datasets (Supplementary Fig. 70). By contrast, there was no significant enrichment of genes associated with schizophrenia^{41,42}, or gene-sets associated with complex disorders that were considered as negative controls such as type-II diabetes, cancer, or height. Subgroup analyses revealed that most enrichment signals were driven by the predominance of neurological abnormalities among the subjects (Supplementary Fig. 71).

BCAs predominantly contribute to developmental anomalies by direct gene truncation

We next asked the fundamental question: “How often does a BCA represent a likely pathogenic mutation that contributes to the subject’s abnormal developmental phenotype?” We built an interpretation framework using categories comparable to those established by ClinVar and the Deciphering Developmental Disorders consortium (DDD)⁴³; however, we restricted interpretation of potential clinical relevance to *Pathogenic* or *Likely Pathogenic*, as detailed below and in Supplementary Table 7. All other variants were interpreted as *Variant of Unknown Significance* (VUS; the predicted impact for each BCA is provided in Supplementary Table 8).

Pathogenic—We compared loci disrupted by BCAs to genes that had been robustly associated with dominant developmental disorders (3 reported cases with dnLoF in OMIM, DDD, and amalgamated large-scale sequencing studies in neurodevelopmental disorders; see Supplementary Note and Supplementary Table 6). In total, 66 subjects (26.6%) harbored *Pathogenic* BCAs that disrupted these previously defined developmental loci either through direct gene disruption or genomic imbalance (Fig. 2c; Table 2; Supplementary Table 9). In the majority of these subjects (53/66), the rearrangement truncated a high confidence syndromic locus. These included known drivers of recurrent microdeletion syndromes (e.g.,

SATB2, MBD5, EHMT1, NFIA, ZBTB20)^{44–48}, loci associated with imprinting disorders (*SNURF-SNRPN*), and genes well-established as highly penetrant loci in developmental disorders (e.g., *CHD7, CHD8, CDKL5, CUL3, DYRK1A, GRIN2B*), as well as more recently implicated genes such as *AHDC1, CTNND2* and *WAC* (Fig. 2c; Table 2; Supplementary Table 9)^{49–51}. Several genes were disrupted in two or more subjects, further confirming their role in developmental anomalies (Table 2). Importantly, ten subjects harbored BCAs that disrupted genes associated with dominant disorders for which the expected phenotype was not reported in the proband (e.g. cardiovascular defects, childhood or late-onset hearing loss, neurodegenerative disorder; Supplementary Table 9). In these subjects, the rearrangements could represent pleiotropy (i.e. disruption of the same locus that can manifest in multiple distinct phenotypes) or incidental findings, and were thus interpreted as VUS. In the remaining 13 subjects with *Pathogenic* BCAs (13/66), genomic imbalances at the breakpoints either overlapped with known microdeletion/microduplication syndromes, or encompassed a gene associated with a dominant developmental disorder (e.g., 12p12.1-p11.22 deletion encompassing *SOX5*; Table 2; Fig. 2c).

Likely Pathogenic—Each specific rearrangement effectively represents a private event, which is a major challenge for interpretation in genomic studies. To interpret variants as *Likely Pathogenic*, we relied on convergent genomic evidence from large-scale datasets, postulating that candidate genes associated with congenital anomalies or early developmental defects would show evidence of intolerance to haploinsufficiency. Thirty-one subjects harbored BCAs that were considered *Likely Pathogenic* (Table 2; Supplementary Tables 8, 10). In 25 subjects, the rearrangement directly disrupted a gene intolerant to dnLoF, and in which dnLoF mutations had been previously reported in isolated cases (1 or 2 subjects, with an additional subject now represented by the BCA in our study; e.g. *CACNA2D3, ROBO2, NFIB*), some of which had strong biological support for involvement in developmental anomalies (*EP400, STXBP5, NRXN3*). There were also several genes disrupted in multiple subjects from the cohort (*NPAS3, PTPRZ1, SYNCRIP*; Table 2, Supplementary Tables 10–11). Two subjects had BCAs likely associated with genomic disorders: one involved a 2p21-p13.3 duplication encompassing *NRXN1*, and the other disrupted the imprinted 11p15 region associated with Silver-Russel syndrome (MIM#180860). In the remaining four subjects with *Likely Pathogenic* BCAs, the rearrangement truncated genes that were associated with developmental disorders, yet only activating or missense mutations had been previously reported (e.g., *CACNA1C* and *GNB1*)^{52,53}, proposing a dosage sensitive model for these loci. Based on these results, we interpreted that 12.5% (31/248) of subjects harbored a BCA that likely contributed to the developmental phenotype by disrupting potentially novel candidate genes or disease mechanisms.

Collectively, these data suggest that 39.1% (97/248) of subjects have a phenotype that can be at least partially explained by haploinsufficiency or dosage alteration of an individual gene or locus (Fig. 2c; Supplementary Tables 8–10). Importantly, the overall diagnostic yield was significantly higher in subsets of the group, such as among those subjects who harbored *de novo* or co-segregating BCAs compared to subjects for whom inheritance was unknown (Fig. 2d), or among subjects who had not been screened clinically by CMA prior to

enrollment (Fig. 2e). Despite these substantial yields, the marked increase in the frequency of BCAs associated with birth defects compared to the general population still suggests that alternative mutational mechanisms, other than direct gene disruption, may account for the developmental defects in a fraction of subjects for which the BCAs were interpreted as VUS.

Positional effects via disruption of long-range regulatory interactions

Clusters of BCA breakpoints within intergenic regions may suggest disruption of strong regulatory elements that contribute to disease manifestation via positional effects.

Alternatively, this could reflect recurrent rearrangements due to fragile sites and/or recombination hotspots. To isolate genomic regions in which an unusual number of BCA breakpoints were localized, we partitioned the genome into 1 Mb bins. Remarkably, one genomic segment, localized to 5q14.3, achieved genome-wide significance and harbored breakpoints from eight independent BCAs ($P=8\times 10^{-9}$; Fig. 3a).

All BCA breakpoints from the 5q14.3 cluster mapped to a region overlapping with the previously described 5q14.3 microdeletion syndrome for which almost 100 subjects have been previously reported, with *MEF2C* as the proposed genetic driver (Fig. 3b)^{54–60}. However, there are reported deletions that do not encompass *MEF2C* (Fig. 3b), and we now report seven BCAs distal to *MEF2C* in subjects with comparable phenotypes to those harboring direct disruption of *MEF2C*, challenging the hypothesis that direct disruption of *MEF2C* is a necessary cause of the syndrome. When combining data from the literature, a total of 11 subjects harbor balanced rearrangement breakpoints localized to the same 1 Mb region within 5q14.3 (Fig. 3b)^{14,54,59}. One BCA directly disrupted *MEF2C* while the remaining 10 mapped to intergenic regions distal to *MEF2C*; none included a breakpoint disrupting a locus of known significance elsewhere in the genome, suggesting that an alternative mechanism to direct gene disruption was operating in the 5q14.3 region. All 10 BCAs with intergenic breakpoints were predicted to disrupt a topologically associated domain (TAD) containing *MEF2C* (Fig. 3b). TADs are structured chromatin domains of increased interactions that typically define a local regulatory unit bridging regulatory elements together with their target genes⁶¹. Their disruption by genomic rearrangements can lead to impaired gene regulation and therefore disease pathogenesis^{62–64}. Correspondingly, in four subjects that harbored BCA breakpoints up to 860 kb distal to *MEF2C*, and for which RNA from lymphoblastoid cell lines (LCLs) was available, *MEF2C* expression was significantly reduced compared to controls (Fig. 3d). These analyses indicate that alteration of the TAD architecture in this genomic disorder region can disrupt normal *MEF2C* expression. When integrated with existing data, the converging clinical features suggest that multiple distinct mutational mechanisms can result in presentation of 5q14.3 microdeletion syndrome: (1) direct disruption of *MEF2C* via dnLoF mutations, (2) deletions including *MEF2C*, and (3) long-range positional effects from deletions and BCAs that do not directly truncate *MEF2C* yet disrupt its normal function via alteration of the TAD structure (Fig. 3c).

Beyond 5q14.3, three other loci were suggestive of an accumulation of BCA breakpoints (2q33.1, 6q14.3 and 14q12, each containing BCA breakpoints from four independent subjects), although they did not reach genome-wide significance ($P=1\times 10^{-4}$; Fig. 3a). At

2q33.1, one BCA disrupted *SATB2*, associated with Glass syndrome and recognized as the established driver of the 2q33.1 microdeletion syndrome^{7,46}, while the remaining three rearrangements were predicted to impact long-range interactions between *SATB2* and its regulatory elements (Supplementary Fig. 72). In the 14q12 cluster, all BCA breakpoints were distal to *FOXG1*, which has been reported in atypical Rett syndrome^{65–68}. The phenotypes associated with all four of these subjects were highly correlated based upon analyses of HPO reported terms (HPO-sim P -value=0.006; see **Methods** and Supplementary Table 11)^{69,70}, and were consistent with the multiple previous reports of subjects with dysregulation of *FOXG1* (Supplementary Fig. 73)^{65–68,71}. At 6q14.3, four BCAs were localized in proximity to *SYNCRIP*, a highly constrained gene in which dnLoF had been reported in two subjects with neurodevelopmental disorders⁷². In one subject the BCA directly disrupted *SYNCRIP*, another subject harbored a breakpoint distal to *SYNCRIP* that was part of a cryptic 6q14.3 deletion encompassing the full gene, though the impact of the other two BCAs was unclear due to their localization to an adjacent contact domain (Supplementary Fig. 74). Finally, a systematic screen identified four additional subjects in which a TAD disruption could represent a positional effect on known syndromic loci associated with a developmental disorder that closely matched the subject's phenotype (*PITX2*, *SLC2A1*, *SOX9*, *SRCAP*; Supplementary Fig. 75–77). In two of these regions, LCLs were available from the corresponding subjects and expression of the proposed driver gene was significantly reduced when compared to controls (*SLC2A1* and *SRCAP*, Supplementary Fig. 75 and 76).

Collectively, 7.3% of subjects harbored a BCA predicted to alter long-range regulatory interactions involving an established syndromic locus with comparable phenotype, recurrently involving *MEF2C*, *SATB2*, and *FOXG1*, while an additional four subjects harbored a BCA that may represent long-range positional effects (two confirmed by expression studies). These data suggest that alterations to TAD structures likely represent a significant component of the deleterious impact of genomic rearrangements.

DISCUSSION

This characterization of BCAs at nucleotide resolution offers new insights into their mechanisms of formation, the properties connected to their rearrangement in the nucleus, and a substantial yield of potentially novel genes associated with human development. These results also emphasize that neither the mere presence of a BCA in a subject with developmental anomalies nor the number of genes it disrupts (if any) provide sufficient prognostic power, but rather that the properties of the specific genes and regions that are altered are the most informative in predicting resultant phenotypes. These data build upon recent studies on genome topology and provide further evidence that alterations to chromosome structure can lead to alternative, yet potentially predictable, pathogenic mechanisms by changing the long-range regulatory architecture of physical interactions and chromatin looping in the nucleus^{62–64,69}. The yield of clinically meaningful results in this study, which ranged from 26.6% to 46.4% of the subjects evaluated, was substantial. Nonetheless, the relative enrichment from cytogenetic studies of BCAs in subjects with developmental abnormalities compared to controls suggests that there are yet additional

alternative pathogenic mechanisms associated with *de novo* chromosomal rearrangements that remain to be discovered^{4,5}.

These data provide an initial vantage of the potential utility of emerging datasets that characterize the nuclear organization of the chromosomes. They propose novel pathogenic mechanisms by which BCAs may operate, which appear to be a consequence of the disruption of long-range interactions between regulatory elements and their target gene^{62–64,69}. Structural variants can indeed easily scramble DNA topology and contact domains with potentially dramatic regulatory consequences. TADs cover a substantial fraction of the genome; therefore, the vast majority of structural variation will perturb one of those domains and cannot constitute a predictive criterion for pathogenicity *per se*. However, these data propose that the recurrent disruption of a TAD encompassing a high confidence locus beyond what is expected by chance, concomitant with strong phenotypic overlap between the carrier of the variant and haploinsufficiency of the locus in independent subjects and demonstrated effect on gene expression, may represent a first step towards highlighting putative positional effects in the human genome. There is clearly a need for sensitive and specific tools to predict such positional effects caused by long-range regulatory perturbations, and to annotate further the morbid genome with more expansive knowledge of these functional interactions. The fraction of BCAs in this study that may be associated with this pathogenic mechanism is therefore just an entrée into their likely significance as a component of the unexplained genetic contribution to human birth defects.

In terms of evaluating diagnostic strategies, this study further highlights limitations of current diagnostic tools such as karyotyping or CMA in interpreting and detecting BCAs^{10,12–15}. While the capability to visualize the chromosomes and detect *de novo* BCAs by traditional karyotyping represented a critical leap in genetic diagnostics, as exemplified by the seminal population cytogenetic studies performed by our late co-author, Dorothy Warburton⁷³, the detection of gross chromosomal abnormalities provides limited prognostic capability. Our data demonstrate that karyotyping significantly underestimates complex rearrangements and is almost always revised by at least a sub-band. Karyotyping is also insensitive to genomic imbalances that cannot be directly visualized (~5–10 Mb). By comparison, CMA is generally recommended as a first-tier diagnostic screen given its sensitivity to detect submicroscopic CNVs, yet it is blind to copy-neutral events such as those described herein. This study provides critical new insights into the fraction of BCAs that can be ascertained by CMA analyses. Compared to cytogenetic estimates suggesting that up to 40% of BCAs resolved as unbalanced rearrangements and could therefore be ascertained using CMA²⁴, whole-genome sequencing in this cohort suggests that, even at the resolution of 100 kb, only about 12% of BCAs involved a genomic imbalance. If we consider only the 102 subjects for whom no CMA was previously performed, this proportion increases to 18.8% at 100 kb resolution and 17.6% at 500 kb resolution, suggesting that 81.2–82.4% of BCAs in this study would be inaccessible to most CMA platforms routinely used in clinical diagnostics. Notably, there is still benefit to an initial CMA screen, as is illustrated by the significantly lower yield of pathogenic BCAs among subjects who had been pre-screened by CMA (19–37%) compared to those who had not (41–64%; Fig. 2e), indicating that a fraction of pathogenic variation in these genomes was captured by the CMA prescreen either in relation to or independent of the BCA.

These data strongly argue for the implementation of technologies capable of detecting both balanced and unbalanced genomic rearrangements. This could be achieved by using a conventional cytogenetic test followed by a reflex WGS analysis when an abnormality is detected, which we have previously demonstrated can provide access to all classes of structural variation in the human genome in a relatively rapid timeframe^{11,74}. Despite its great promise, it is important to recognize the limitations of massively parallel sequencing in routine cytogenetic practice. This study used large-insert jumping libraries to maximize physical coverage and minimize cost per base of genome covered. Yet these analyses failed to reveal breakpoints in 9% of BCAs tested, and our simulations indicate that at large sample sizes, we would anticipate ~7–8% of breakpoints to be undetectable by short-read sequencing. As sequencing technologies and analytical capabilities improve, this component of the variant spectrum that are recalcitrant to short-read sequencing will become more tractable to genomic approaches, and the future implementation of long-read sequencing may revolutionize the capacity to survey currently inaccessible segments of the human genome^{75,76}.

In conclusion, these data indicate that *de novo* BCAs represent a highly penetrant mutational class in human disease, and that their delineation can provide prognostic insights not available at current cytogenetic resolution. Although encouraging, this yield does not explain all of the developmental anomalies in this cohort and suggests that additional pathogenic mechanisms await discovery. A meaningful fraction may be attributable to novel genes or regulatory alterations, but additional pathogenic mechanisms remain to be explored such as recessive modes of inheritance, gene fusions, disruption of imprinted regions, enhancer adoption^{69,77}, and more complex oligogenic models. Evaluation of extremely large cohorts will be required to resolve further such mechanisms, and characterization of BCAs in control populations would benefit annotation of the morbid human genome and interpretation of the biological and clinical consequences of its structural rearrangement.

ONLINE METHODS

Subject Ascertainment

Subjects were enrolled through cytogenetic reference centers including DGAP (the Developmental Genome Anatomy Project) of Brigham and Women's Hospital and Massachusetts General Hospital, Boston, MA; Mayo Clinic, Rochester, MN; University Medical Center, Utrecht, NL; Radboud University Medical Center, Nijmegen, NL. Enrollment was based on the presence of a developmental anomaly and concomitant BCA (*de novo* or that segregated with the abnormal phenotype) detected by karyotyping, and exclusion of clinically significant genomic copy number imbalances using chromosomal microarray analyses (SNP array or array-CGH) when possible (171/273 tested subjects; Supplementary Fig. 1). In the majority of cases the BCA was confirmed to have arisen *de novo* by karyotyping (184/273) or segregated with a developmental phenotype in the family (14/273). In a subset of subjects: (1) the BCA was inherited but the phenotype of the transmitting parent was not available (3/273); (2) one parent was available and did not harbor the BCA (4/273); or (3) neither parents were available for testing (68/273). An informed consent was obtained from all subjects or their legal representative for

participation in the study. All studies were approved by respective Institutional Review Boards.

Whole-genome sequencing using large-insert jumping libraries

Blood samples were collected from all subjects and their parents when available. DNA was extracted from blood or from freshly derived LCLs. Samples were prepared using multiple sequencing methods over several years (Supplementary Table 1). Most samples were sequenced using whole-genome large-insert jumping library preparation protocols for subsequent Illumina sequencing: 149 using our 2×25-bp EcoP151 protocol^{11,80}, 59 using a variant of our jumping library protocol in which we randomly shear circularized DNA, which enables longer reads (paired-end 50 bp, see Supplementary Note) and 19 using standard Illumina mate-pair protocols. All large-insert sequencing methods allowed generation of paired-end reads with median insert size of 2.5–3.5 kb as opposed to 300 bp using conventional methods. A subset of samples were prepared with standard short-insert paired-end protocols (n=12) or targeted sequencing of the breakpoints based on previous positional cloning to narrow the breakpoint regions (n=34), as previously described^{7,11,81}. Of note, 87 BCAs had been initially reported in the literature, though many had not been mapped to sequence resolution (Supplementary Table 1).

Digitalization and homogenization of reported phenotypes

Clinical description was converted for all 273 subjects into standardized terms using Human Phenotype Ontology (HPO; Supplementary Table 2)¹⁸. Such digitalization allowed systematic comparison of phenotypes between subjects carrying BCAs that disrupted the same gene, as well as between subjects with a disrupted gene to previously described subjects using Phenomizer⁸². HPO-sim was used to compute phenotypic similarity scores between subjects sharing the disruption of the same gene or locus compared to random expectations (Supplementary Table 11). *P*-values were generated as the proportion of simulated scores greater than the observed probands' score, alike described by the authors⁷⁰. HPO-digitalization also allowed the generation of heatmaps summarizing the correlation between disrupted genes and phenotypes reported in subjects. For each gene, the number of HPO terms belonging each broad HPO categories was computed¹⁸. The matrix was then z-score transformed by gene, and clustering was performed using a distance matrix of correlation coefficients and average agglomeration (Figure 4).

BCA discovery pipeline and breakpoint inference

All computational analyses have been previously described^{74,83}. In brief, reads were reverse-complemented and aligned using BWA⁸⁴. Anomalous read-pairs in terms of insert size, mate mapping, or mate orientation were extracted using Sambamba and clustered using ReadPairCluster, our single-linkage clustering algorithm^{11,85}. Anomalous read-pair clusters meeting our established thresholds of structural variation were subsequently classified based on their read-pair orientation signature into the following categories: deletions, insertions, inversions, and translocations⁸³. When no clusters were found that matched the proposed karyotype, BAM files were agnostically analyzed and manually inspected for anomalous pairs or split reads. Breakpoints were successfully identified in 248 of 273 cases, leading to an overall breakpoint fine-mapping yield of 91%. All subsequent counts and yields were

computed relative to mapped cases (n=248). For the remaining 25 unmapped cases, no breakpoints were identified in proximity to the karyotype interpretation following extensive analyses and visual inspection. For the majority of these latter unresolved cases, one or more breakpoints were interpreted by the karyotype to localize near centromeres heterochromatic regions, or within segmental duplications, which are recognized to be blind spots for short-read alignments. All large genomic imbalances predicted to be connected to BCA breakpoints following rearrangement reconstruction were confirmed to have aberrant depth of coverage using a custom R-script (CNView: <https://github.com/RCollins13/CNView>).

When additional DNA was available, precise breakpoint junctions were delineated at base-pair resolution by Sanger sequencing and final breakpoints coordinates were reported; else the reported coordinates reflect the closest breakpoint estimates based on the resolution of the jumping libraries (Supplementary Table 3). A total of 82.7% (725/876) of the reported breakpoints could be tested by Sanger sequencing given DNA availability, among which 662 were confirmed yielding a minimum estimate of 91.3% (662/725) sensitivity for our mapping method.

Molecular signature of BCA breakpoints

As previously described²², we processed all Sanger sequences from validated breakpoints with the BWA Smith-Waterman algorithm (modified parameters $z\ 100\ -t\ 3\ -H\ -T\ 1$) to retrieve precise breakpoint coordinates as well as infer the associated microhomology, micro-insertions or blunt end signature. This approach was sufficiently high-throughput to enable the direct comparison of BCA breakpoints with a large set of deletion breakpoints published by Abyzov *et al.*²⁶, at the cost of not allowing concomitant microhomology and base insertions at breakpoints.

Monte-Carlo randomization tests and associated statistics

A Browser Extensible Data (BED) file containing GRCh37/hg19 genomic coordinates of all 876 breakpoints detected by WGS was used as the input. One simulation consisted of generating random coordinates based on each pair of input coordinates, conserving the size of the feature as well as the intra-chromosomal distance when several breakpoints were localized to the same chromosome in a single individual. N-masked regions were excluded from simulations for consistency as they were excluded from the initial alignment mapping. Simulations were repeated 100,000 times. The number of unique intersections between the shuffled file and a BED-file containing features of interest (gene-sets, regulatory elements, etc.) was retrieved for each simulation, and the final sets of simulations delineated the expected distribution on intersections under the null hypothesis. The observed value of intersected features in this study was compared to this expected distribution. Empirical Monte-Carlo *P-values* were indicated, and were calculated as follows: $P\text{-value} = (r + 1)/(n + 1)$, where r is the number of observations within the set of simulations that are at least as extreme as the one observed, and n is the total number of simulations⁸⁶. References for all functional element datasets and genesets that were used to test for enrichment at breakpoints in the cohort are detailed in Supplementary Table 12.

To isolate genomic regions in which an unusual number of BCA breakpoints were localized, we partitioned the genome into 1 Mb bins using a sliding window of 100 kb, and counted the number of BCA breakpoints coming from independent subjects. The same approach was performed for 100,000 sets of simulated breakpoints generated as detailed previously. *P*-values were computed by comparing observed to expected cluster sizes after 100,000 Monte Carlo randomizations, and corrected for the total number of windows interrogated. Genome-wide significance was achieved for clusters with *P*-values below 1.6×10^{-6} .

BCA outcome interpretation

To build reference lists of genes associated with dominant developmental disorders we amalgamated data from multiple large-scale exome sequencing, genome sequencing, or CNV studies investigating developmental (*e.g.* DDD consortium) and neurodevelopmental disorders (mostly intellectual disability, autism, and epilepsy cohorts; see Supplementary Note and Supplementary Table 6 for detailed references). We then built our interpretation using standard categories comparable to those established by ClinVar and the Deciphering Developmental Disorders consortium (DDD)⁴³, as detailed below and in Supplementary Table 7.

Pathogenic: Confirmed Loci associated with developmental disorders—Any gene with three or more *de novo* LoF mutations (frameshift, nonsense or splice mutation, CNV, or BCA) reported from independent cases in those amalgamated studies or in OMIM was considered as high confidence for a particular phenotype, and any BCA impacting one of those loci was therefore considered to be *Pathogenic* (Supplementary Table 9).

Likely Pathogenic: Novel candidate genes or mechanisms—To evaluate the impact of the remaining BCAs and the genes they likely impacted, we relied on convergent genomic evidence from other large-scale datasets to prioritize which gene would most likely contribute to the subject's phenotype. Multiple BCAs were considered to be *Likely Pathogenic*, based on various evidences (Supplementary Table 10):

1. Disruption of a likely risk factor: Disruption of one copy of a gene in which one or two dnLoF mutations had been previously reported **and** which demonstrated significant constraint (top 10% of constrained genes)^{28,29}
2. Novel mechanisms: Disruption of a gene established as associated with dominant developmental disorders yet with a distinct mutation type (*e.g.* activating or missense mutations while we reported LoF)
3. Disruption of long-range interactions: BCA breakpoints located in the vicinity of a gene associated with dominant developmental disorders in a subject with a consistent phenotype, and predicted to impact long-range regulatory interactions.

VUS—All BCAs impacting genes not fitting in any of the above-mentioned categories were considered as VUS.

Predicted disruption of contact domains by BCAs

Topological associated domains (TADs) and predicted loops for lymphoblastoid cells were retrieved from Dixon *et al.* and Rao *et al.*^{17,61}, and genes contained within a domain for which at least one of its insulating boundaries was disrupted by a BCA were assessed. Only genes that had been previously robustly associated with dominant developmental disorders (*i.e.*, with dnLoF reported in three or more subjects) were considered for potential positional effects. A detailed comparison of the reported phenotypes in the corresponding subjects to phenotypes associated with disrupted genes in the literature was performed. For subjects identified with a BCA of plausible positional effect, the region was visualized using Juicebox⁸⁷ (Supplementary Fig. 72–77). Heatmaps represent observed intrachromosomal interactions in GM12878 lymphoblastoid cells in a specific window; previously reported contact domains (regions of increased contact, not necessarily materializing as loops) and loops (sites of increased focal contacts indicating the presence of a loop) were indicated^{17,61}, as well as the RefSeq genes located in the region.

Measuring gene expression from lymphoblasts

In subjects for whom the BCA was suspected to result in positional effects and for whom LCLs derived from blood were available, gene expression was investigated by quantitative RT-PCR. LCLs were not tested for mycoplasma contamination. Total RNA was extracted from LCLs using TRIzol® (Invitrogen) followed by RNeasy Mini Kit (Qiagen) column purification. cDNA was synthesized from 750 ng of extracted RNA using SuperScript® II Reverse Transcriptase (ThermoFisher Scientific with oligo(dT), random hexamers, and RNase inhibitor. Quantitative RT-PCR was performed for mRNA expression of genes of interest in the following subjects (*MEF2C*: DGAP131, DGAP191, DGAP218, DGAP222; *SATB2*: DGAP237; *SLC2A1*: DGAP170; *SRCAP*: DGAP134) using custom designed primers (see Supplementary Note). *ACTB*, *GAPDH* and *POLR2A* were each used as independent endogenous controls. Custom designed primers (0.75 µM final), cDNA (1:100 final) and nuclease-free water were added to the LightCycler® 480 SYBR Green I Master Mix (Roche) for a final 10 µL reaction volume. A LightCycler® 480 (Roche) was used for data acquisition. Values of each individual (subject or control) were obtained in triplicates of similar variance. Results of triplicates for each gene of interest were normalized against the average of the three endogenous controls (*ACTB*, *GAPDH* and *POLR2A*). Normalized expression levels were set in relation to eight age and sex-matched controls for the genes of interest *SATB2*, *SLC2A1* and *SRCAP*, or 16 (eight males, eight females) age-matched controls for the gene of interest *MEF2C*, using the Ct method. Results are expressed as fold-change relative to the averaged control individuals. The significance of differential gene expression from a subject in comparison to controls was tested using a two-sided Wilcoxon Mann-Whitney test. All qRT-PCR results were independently replicated twice in the laboratory.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Authors

Claire Redin^{1,2,3}, Harrison Brand^{1,2,3}, Ryan L. Collins^{1,2,3,4}, Tammy Kammin⁵, Elyse Mitchell⁶, Jennelle C. Hodge^{6,7,8}, Carrie Hanscom^{1,2,3}, Vamsee Pillalamarri^{1,2,3}, Catarina M. Seabra^{1,2,3,9}, Mary-Alice Abbott¹⁰, Omar A. Abdul-Rahman¹¹, Erika Aberg¹², Rhett Adley¹, Sofia L. Alcaraz-Estrada¹³, Fowzan S. Alkuraya¹⁴, Yu An^{1,15}, Mary-Anne Anderson¹⁶, Caroline Antolik^{1,2,3}, Kwame Anyane-Yeboah¹⁷, Joan F. Atkin^{18,19}, Tina Bartell²⁰, Jonathan A. Bernstein²¹, Elizabeth Beyer²², Ian Blumenthal¹, Ernie M.H.F. Bongers²³, Eva H. Brilstra²⁴, Chester W. Brown^{25,26}, Hennie T. Brüggerwirth²⁷, Bert Callewaert²⁸, Colby Chiang¹, Ken Corning²⁹, Helen Cox³⁰, Edwin Cuppen²⁴, Benjamin B. Currall^{1,5,31}, Tom Cushing³², Dezso David³³, Matthew A. Dearnorff^{34,35}, Annelies Dheedene²⁸, Marc D'Hooghe³⁶, Bert B.A. de Vries²³, Dawn L. Earl³⁷, Heather L. Ferguson⁵, Heather Fisher³⁸, David R. FitzPatrick³⁹, Pamela Gerrol⁵, Daniela Giachino⁴⁰, Joseph T. Glessner^{1,2,3}, Troy Gliem⁶, Margo Grady⁴¹, Brett H. Graham^{25,26}, Cristin Griffis²², Karen W. Gripp⁴², Andrea L. Gropman⁴³, Andrea Hanson-Kahn⁴⁴, David J. Harris^{45,46}, Mark A. Hayden⁵, Rosamund Hill⁴⁷, Ron Hochstenbach²⁴, Jodi D. Hoffman⁴⁸, Robert J. Hopkin^{49,50}, Monika W. Hubshman^{51,52,53}, A. Micheil Innes⁵⁴, Mira Irons⁵⁵, Melita Irving^{56,57}, Jessie C. Jacobsen⁵⁸, Sandra Janssens²⁸, Tamison Jewett⁵⁹, John P. Johnson⁶⁰, Marjolijn C. Jongmans²³, Stephen G. Kahler⁶¹, David A. Koolen²³, Jerome Korzelius²⁴, Peter M. Kroisel⁶², Yves Lacassie⁶³, William Lawless¹, Emmanuelle Lemyre⁶⁴, Kathleen Leppig^{65,66}, Alex V. Levin⁶⁷, Haibo Li⁶⁸, Hong Li⁶⁸, Eric C. Liao^{69,70,71}, Cynthia Lim^{61,72}, Edward J. Lose⁷³, Diane Lucente¹, Michael J. Macera⁷⁴, Poornima Manavalan¹, Giorgia Mandrile⁴⁰, Carlo L. Marcelis²³, Lauren Margolin⁷⁵, Tamara Mason⁷⁵, Diane Masser-Frye⁷⁶, Michael W. McClellan⁷⁷, Cinthya J. Zepeda Mendoza^{5,78}, Björn Menten²⁸, Sjors Middelkamp²⁴, Liya R. Mikami^{79,80}, Emily Moe²², Shehla Mohammed⁵⁶, Tarja Mononen⁸¹, Megan E. Mortenson^{59,82}, Graciela Moya⁸³, Aggie W. Nieuwint⁸⁴, Zehra Ordulu^{5,78}, Sandhya Parkash^{12,85}, Susan P. Pauker^{78,86}, Shahrin Pereira⁵, Danielle Perrin⁷⁵, Katy Phelan⁸⁷, Raul E. Piña Aguilar^{13,88}, Pino J. Poddighe⁸⁴, Giulia Pregnò⁴⁰, Salmo Raskin⁷⁹, Linda Reis⁸⁹, William Rhead⁹⁰, Debra Rita⁹¹, Ivo Renkens²⁴, Filip Roelens⁹², Jayla Ruliera¹⁶, Patrick Rump⁹³, Samantha L.P. Schilit^{30,78}, Ranad Shaheen¹⁴, Rebecca Sparkes⁵⁴, Erica Spiegel¹⁷, Blair Stevens⁹⁴, Matthew R. Stone^{1,2,3}, Julia Tagoe⁹⁵, Joseph V. Thakuria^{78,96}, Bregje W. van Bon²³, Jiddeke van de Kamp⁸⁴, Ineke van Der Burgt²³, Ton van Essen⁹³, Conny M. van Ravenswaaij-Arts⁹³, Markus J. van Roosmalen²⁴, Sarah Vergult²⁸, Catharina M.L. Volker-Touw²⁴, Dorothy P. Warburton⁹⁷, Matthew J. Waterman^{1,98}, Susan Wiley⁹⁹, Anna Wilson¹, Maria de la Concepcion A. Yerena-de Vega¹⁰⁰, Roberto T. Zori¹⁰¹, Brynn Levy¹⁰², Han G. Brunner^{23,103}, Nicole de Leeuw²³, Wigard P. Kloosterman²⁴, Erik C. Thorland⁶, Cynthia C. Morton^{3,5,78,104,105}, James F. Gusella^{1,3,31}, and Michael E. Talkowski^{1,2,3,*}

Affiliations

¹Molecular Neurogenetics Unit, Center for Human Genetic Research, Department of Neurology, Massachusetts General Hospital, Boston, MA 02114, USA ²Psychiatric

and Neurodevelopmental Genetics Unit, Center for Human Genetic Research, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA ³Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA 02141, USA ⁴Program in Bioinformatics and Integrative Genomics, Division of Medical Sciences, Harvard Medical School, Boston, MA 02115, USA ⁵Department of Obstetrics and Gynecology, Brigham and Women's Hospital, Boston, MA 02115, USA ⁶Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55902, USA ⁷Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA ⁸Department of Pediatrics, University of California Los Angeles, Los Angeles, CA 90095, USA ⁹GABBA Program, University of Porto, Porto, Portugal ¹⁰Medical Genetics, Baystate Medical Center, Springfield, MA 01199, USA ¹¹Department of Pediatrics, University of Mississippi Medical Center, Jackson, MS 39216, USA ¹²Maritime Medical Genetics Service, IWK Health Centre, Halifax, Nova Scotia, Canada ¹³Medical Genomics Division, Centro Medico Nacional 20 de Noviembre, ISSSTE, Mexico City, Mexico ¹⁴Department of Genetics, King Faisal Specialist Hospital and Research Center, MBC-03 PO BOX 3354, Riyadh 11211, Saudi Arabia ¹⁵The Institutes of Biomedical Sciences (IBS) of Shanghai Medical School and MOE Key Laboratory of Contemporary Anthropology, Fudan University, Shanghai, China ¹⁶Center for Human Genetic Research DNA and Tissue Culture Resource, Boston, MA 02114, USA ¹⁷Division of Clinical Genetics, Columbia University Medical Center, New York, NY 10032, USA ¹⁸Department of Pediatrics, The Ohio State University College of Medicine, Columbus, OH 43210, USA ¹⁹Division of Molecular and Human Genetics, Nationwide Children's Hospital, Columbus, OH 43205, USA ²⁰Kaiser Permanente, Genetics Department, Sacramento, CA 95815, USA ²¹Department of Pediatrics, Stanford University School of Medicine, Stanford, CA 94305, USA ²²Children's Hospital of Wisconsin and Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI 53226, USA ²³Department of Human Genetics, Radboud Institute for Molecular Life Sciences and Donders Institute for Brain, Cognition and Behavior, Radboud University Medical Center, Nijmegen 6500 HB, the Netherlands ²⁴Department of Genetics, Division of Biomedical Genetics, Center for Molecular Medicine, University Medical Center Utrecht, 3508 AB Utrecht, The Netherlands ²⁵Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA ²⁶Department of Genetics, Texas Children's Hospital, Houston, TX 77054, USA ²⁷Department of Clinical Genetics, Erasmus University Medical Centre, PO BOX 2040, 3000 CA Rotterdam, The Netherlands ²⁸Center for Medical Genetics, Ghent University, De Pintelaan 185, 9000 Ghent, Belgium ²⁹Greenwood Genetic Center, Columbia, SC, 29201, USA ³⁰West Midlands Regional Clinical Genetics Unit, Birmingham Women's Hospital, Edgbaston, Birmingham B15 2TG, England, UK ³¹Department of Genetics, Harvard Medical School, Boston, MA 02115, USA ³²University of New Mexico, School of Medicine, Department of Pediatrics, Division of Pediatric Genetics, Albuquerque, NM 87131, USA ³³Department of Human Genetics, National Health Institute Doutor Ricardo Jorge, Lisbon, Portugal

³⁴Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA ³⁵Division of Human Genetics, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA ³⁶Department of Neurology and Child Neurology, Algemeen Ziekenhuis Sint-Jan, Brugge, Belgium ³⁷Seattle Children's, Seattle, Washington, WA 98105, USA ³⁸Mount Sinai West Hospital, New York, NY 10019, USA ³⁹Medical Research Council Human Genetics Unit, Institute of Genetic and Molecular Medicine, University of Edinburgh, Western General Hospital, Edinburgh EH4 2XU, UK ⁴⁰Medical Genetics Unit, Department of Clinical and Biological Sciences, University of Torino, Italy ⁴¹UW Cancer Center at ProHealth Care, Waukesha, Wisconsin, WI 53188, USA ⁴²Sidney Kimmel Medical School at Thomas Jefferson University, Philadelphia, PA 19107, USA ⁴³Children's National Medical Center, Washington, DC 20010, USA ⁴⁴Departments of Pediatrics and Genetics, Stanford University School of Medicine, Stanford, CA 94305, USA ⁴⁵Division of Genetics, Boston Children's Hospital, Boston, MA 02115, USA ⁴⁶Department of Pediatrics, Harvard Medical School, Boston, MA 02115, USA ⁴⁷Department of Neurology, Auckland City Hospital, Auckland, New Zealand ⁴⁸Department of Pediatrics, Division of Genetics, Boston Medical Center, MA 02118, USA ⁴⁹Cincinnati Children's Hospital Medical Center, Division of Human Genetics, Cincinnati, OH 45229, USA ⁵⁰Department of Pediatrics, University of Cincinnati College Medicine, Cincinnati, OH 45267, USA ⁵¹Pediatric Genetics Unit, Schneider Children's Medical Center of Israel, Petach Tikva 49202, Israel ⁵²Raphael Recanati Genetic Institute, Rabin Medical Center, Petach Tikva 49100, Israel ⁵³Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel ⁵⁴Department of Medical Genetics, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada ⁵⁵Academic Affairs, American Board of Medical Specialties, Chicago, IL 60654, USA ⁵⁶Department of Clinical Genetics, Guy's and St Thomas' NHS Foundation Trust, London, UK ⁵⁷Division of Medical and Molecular Genetics, King's College London, UK ⁵⁸Centre for Brain Research and School of Biological Sciences, The University of Auckland, Auckland, New Zealand ⁵⁹Department of Pediatrics, Wake Forest School of Medicine, Winston Salem, NC 27157, USA ⁶⁰Shodair Children's Hospital, Molecular Genetics Department, Helena, MT 59601, USA ⁶¹Division of Genetics and Metabolism, Arkansas Children's Hospital, Little Rock, AR 72202, USA ⁶²Institute of Human Genetics, Medical University of Graz, Graz, Austria ⁶³Department of Pediatrics at Louisiana State University Health Sciences Center (LSUHSC) and Children's Hospital, New Orleans, LA 70118, USA ⁶⁴Department of Pediatrics, University of Montreal, CHU Sainte-Justine, Montréal QC, Canada ⁶⁵Division of Medical Genetics, Department of Medicine, University of Washington, Seattle, WA 98195, USA ⁶⁶Clinical Genetics, Group Health Cooperative, Seattle, WA 98112, USA ⁶⁷Wills Eye Hospital, Thomas Jefferson University, Philadelphia, PA 19107, USA ⁶⁸Center for Reproduction and Genetics, The affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, Jiangsu, China ⁶⁹Center for Regenerative Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA ⁷⁰Division of Plastic and Reconstructive Surgery, Massachusetts General Hospital, Boston, MA 02114, USA

⁷¹Harvard Stem Cell Institute, Cambridge, MA 02138, USA ⁷²Virginia G. Piper Cancer Center at HonorHealth, Scottsdale, AZ 85258, USA ⁷³Department of Genetics, University of Alabama at Birmingham (UAB), Birmingham, AL 35233, USA ⁷⁴New York-Presbyterian Hospital, Columbia University Medical Center, New York, NY 10032, USA ⁷⁵Program in Medical and Population Genetics and Genomics Platform, Broad Institute of Harvard and MIT, Cambridge, MA 02141, USA ⁷⁶Department of Genetics, Rady Children's Hospital San Diego, CA 92123, USA ⁷⁷Department of Obstetrics and Gynecology, Madigan Army Medical Center, Tacoma, WA 98431, USA ⁷⁸Harvard Medical School, Boston, MA 02115, USA ⁷⁹Group for Advanced Molecular Investigation, Graduate Program in Health Sciences, School of Medicine, Pontifícia Universidade Católica do Paraná, Curitiba, Paraná, Brazil ⁸⁰Centro Universitário Autônomo do Brasil (Unibrasil), Curitiba, Paraná, Brazil ⁸¹Department of Clinical Genetics, Kuopio University Hospital, Finland ⁸²Novant Health Derrick L. Davis Cancer Center, Winston Salem, NC 27103, USA ⁸³GENOS Laboratory, Buenos Aires, Argentina ⁸⁴Department of Clinical Genetics, VU University Medical Center, De Boelelaan 1117, Amsterdam 1081 HV, The Netherlands ⁸⁵Department of Pediatrics, Maritime Medical Genetics Service, IWK Health Centre, Dalhousie University, Halifax, Nova Scotia, Canada ⁸⁶Medical Genetics, Harvard Vanguard Medical Associates, Watertown, MA 02472, USA ⁸⁷Hayward Genetics Program, Department of Pediatrics, Tulane University School of Medicine, New Orleans, LA 70112, USA ⁸⁸School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen, United Kingdom ⁸⁹Department of Pediatrics and Children's Research Institute, Medical College of Wisconsin, Milwaukee, WI 53226, USA ⁹⁰Children's Hospital of Wisconsin and Departments of Pediatrics and Pathology, Medical College of Wisconsin, Milwaukee, WI 53226, USA ⁹¹Midwest Diagnostic Pathology, Aurora Clinical Labs, Rosemont, IL 60018, USA ⁹²Algemeen Ziekenhuis Delta, Roeselare, Belgium ⁹³University of Groningen, University Medical Center Groningen, Department of Genetics, PO Box 30.001, 9700RB Groningen, The Netherlands ⁹⁴McGovern Medical School at The University of Texas Health Science Center at Houston, TX 77030, USA ⁹⁵Genetic Services, Alberta Health Services, Alberta T1J 4L5, Canada ⁹⁶Division of Medical Genetics, Massachusetts General Hospital, Boston, MA 02114, USA ⁹⁷Department of Clinical Genetics and Development, Columbia University Medical Center, New York, NY 10032, USA ⁹⁸Eastern Nazarene College, Department of Biology, Quincy, MA 02170, USA ⁹⁹Cincinnati Children's Hospital Medical Center, University of Cincinnati, OH 45229, USA ¹⁰⁰Laboratory of Genetics, Centro Medico Nacional 20 de Noviembre, ISSSTE, Mexico City, Mexico ¹⁰¹Division of Pediatric Genetics & Metabolism, University of Florida, Gainesville, FL 32610, USA ¹⁰²Department of Pathology, Columbia University, New York, NY 10032, USA ¹⁰³Department of Clinical Genetics, Maastricht University Medical Centre, Universiteitssingel 50, 6229 ER Maastricht, The Netherlands ¹⁰⁴Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, USA ¹⁰⁵Division of Evolution and Genomic Sciences, School of Biological Sciences, University of Manchester, Manchester Academic Health Science Center, Manchester, UK

Acknowledgments

We are infinitely grateful for the seminal work led by our co-author, Prof. Dorothy Warburton, who passed away during review of this manuscript. Dr. Warburton was a pioneer in cytogenetic research and a close colleague, mentor, and friend to so many in the cytogenetics community. We wish to thank all subjects and families who have been enrolled in this study, as well as the countless genetic counselors and clinical geneticists who contributed to the ascertainment of subjects. This study was supported by: the National Institutes of Health (grant GM061354 to M.E.T., J.F.G., C.C.M. and E.L.; grants MH095867 and HD081256 to M.E.T.), the March of Dimes (6-FY15-255 to M.E.T.), the European Molecular Biology Organization and the Marie Curie Actions of the European Commission (fellowship EMBO ALTF-183-2015 to C.R.), the Bettencourt-Schueller Foundation (young investigator award to C.R.), the Philippe Foundation (award to C.R.), the Harvard Medical School–Portugal Program in Translational and Clinical Research and Health Information (Fundação para a Ciência e a Tecnologia, HMSP-ICT/0016/2013 to C.C.M and D.D.), the National Science Foundation (NSF Graduate Research Fellowship DGE1144152 to S.L.P.S.), the Fund for Scientific Research – Flanders (B.C. and S.V. are respectively a FWO senior clinical investigator and a FWO postdoctoral researcher), Clinical Medicine Science and Technology Projects of Jiangsu Province (grant BL2013019 to Ha.L. and Ho.L.), the Suzhou Key Medical Center (grant Szzx201505 to Ha.L. and Ho.L.), and the Royal Society of New Zealand (Rutherford Discovery Fellowship to J.C.J.). This study was also supported by the Desmond and Ann Heathwood MGH Research Scholars award to M.E.T

References

1. Jacobs PA, Melville M, Ratcliffe S, Keay AJ, Syme J. A cytogenetic survey of 11,680 newborn infants. *Ann Hum Genet.* 1974; 37:359–376. [PubMed: 4277977]
2. Nielsen J, Wohler M. Chromosome abnormalities found among 34,910 newborn children: results from a 13-year incidence study in Aarhus, Denmark. *Hum Genet.* 1991; 87:81–83. [PubMed: 2037286]
3. Ravel C, Berthaut I, Bresson JL, Siffroi JP. Genetics Commission of the French Federation of C. Prevalence of chromosomal abnormalities in phenotypically normal and fertile adult males: large-scale survey of over 10,000 sperm donor karyotypes. *Hum Reprod.* 2006; 21:1484–1489. [PubMed: 16484311]
4. Funderburk SJ, Spence MA, Sparkes RS. Mental retardation associated with “balanced” chromosome rearrangements. *Am J Hum Genet.* 1977; 29:136–141. [PubMed: 848489]
5. Marshall CR, et al. Structural variation of chromosomes in autism spectrum disorder. *Am J Hum Genet.* 2008; 82:477–488. [PubMed: 18252227]
6. McKusick VA, Amberger JS. The morbid anatomy of the human genome: chromosomal location of mutations causing disease. *J Med Genet.* 1993; 30:1–26. [PubMed: 8423603]
7. Talkowski ME, et al. Sequencing chromosomal abnormalities reveals neurodevelopmental loci that confer risk across diagnostic boundaries. *Cell.* 2012; 149:525–537. [PubMed: 22521361]
8. Weischenfeldt J, Symmons O, Spitz F, Korbel JO. Phenotypic impact of genomic structural variation: insights from and for human disease. *Nat Rev Genet.* 2013; 14:125–138. [PubMed: 23329113]
9. Warburton D. Current techniques in chromosome analysis. *Pediatr Clin North Am.* 1980; 27:753–769. [PubMed: 6161332]
10. Talkowski ME, et al. Next-generation sequencing strategies enable routine detection of balanced chromosome rearrangements for clinical diagnostics and genetic research. *Am J Hum Genet.* 2011; 88:469–481. [PubMed: 21473983]
11. Talkowski ME, et al. Clinical diagnosis by whole-genome sequencing of a prenatal sample. *N Engl J Med.* 2012; 367:2226–2232. [PubMed: 23215558]
12. Schluth-Bolard C, et al. Breakpoint mapping by next generation sequencing reveals causative gene disruption in patients carrying apparently balanced chromosome rearrangements with intellectual deficiency and/or congenital malformations. *J Med Genet.* 2013; 50:144–150. [PubMed: 23315544]
13. Utami KH, et al. Detection of chromosomal breakpoints in patients with developmental delay and speech disorders. *PLoS One.* 2014; 9:e90852. [PubMed: 24603971]

14. Vergult S, et al. Mate pair sequencing for the detection of chromosomal aberrations in patients with intellectual disability and congenital malformations. *Eur J Hum Genet.* 2014; 22:652–659. [PubMed: 24105367]
15. Tabet AC, et al. Complex nature of apparently balanced chromosomal rearrangements in patients with autism spectrum disorder. *Mol Autism.* 2015; 6:19. [PubMed: 25844147]
16. Jin F, et al. A high-resolution map of the three-dimensional chromatin interactome in human cells. *Nature.* 2013; 503:290–294. [PubMed: 24141950]
17. Rao SS, et al. A 3D map of the human genome at kilobase resolution reveals principles of chromatin looping. *Cell.* 2014; 159:1665–1680. [PubMed: 25497547]
18. Kohler S, et al. The Human Phenotype Ontology project: linking molecular biology and disease through phenotype data. *Nucleic Acids Res.* 2014; 42:D966–974. [PubMed: 24217912]
19. Meyerson M, Pellman D. Cancer genomes evolve by pulverizing single chromosomes. *Cell.* 2011; 144:9–10. [PubMed: 21215363]
20. Stephens PJ, et al. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. *Cell.* 2011; 144:27–40. [PubMed: 21215367]
21. Kloosterman WP, et al. Chromothripsis as a mechanism driving complex de novo structural rearrangements in the germline. *Hum Mol Genet.* 2011; 20:1916–1924. [PubMed: 21349919]
22. Chiang C, et al. Complex reorganization and predominant non-homologous repair following chromosomal breakage in karyotypically balanced germline rearrangements and transgenic integration. *Nat Genet.* 2012; 44:390–397. S391. [PubMed: 22388000]
23. Baca SC, et al. Punctuated evolution of prostate cancer genomes. *Cell.* 2013; 153:666–677. [PubMed: 23622249]
24. De Gregori M, et al. Cryptic deletions are a common finding in “balanced” reciprocal and complex chromosome rearrangements: a study of 59 patients. *J Med Genet.* 2007; 44:750–762. [PubMed: 17766364]
25. Zhang F, et al. The DNA replication FoSTeS/MMBIR mechanism can generate genomic, genic and exonic complex rearrangements in humans. *Nat Genet.* 2009; 41:849–853. [PubMed: 19543269]
26. Abyzov A, et al. Analysis of deletion breakpoints from 1,092 humans reveals details of mutation mechanisms. *Nat Commun.* 2015; 6:7256. [PubMed: 26028266]
27. Djebali S, et al. Landscape of transcription in human cells. *Nature.* 2012; 489:101–108. [PubMed: 22955620]
28. Petrovski S, Wang Q, Heinzen EL, Allen AS, Goldstein DB. Genic intolerance to functional variation and the interpretation of personal genomes. *PLoS Genet.* 2013; 9:e1003709. [PubMed: 23990802]
29. Samocha KE, et al. A framework for the interpretation of de novo mutation in human disease. *Nat Genet.* 2014; 46:944–950. [PubMed: 25086666]
30. Iossifov I, et al. The contribution of de novo coding mutations to autism spectrum disorder. *Nature.* 2014; 515:216–221. [PubMed: 25363768]
31. Berg JS, et al. An informatics approach to analyzing the incidentalome. *Genet Med.* 2013; 15:36–44. [PubMed: 22995991]
32. Darnell JC, et al. FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism. *Cell.* 2011; 146:247–261. [PubMed: 21784246]
33. Ascano M Jr, et al. *Nature.* 2012; 492:382–386. [PubMed: 23235829]
34. Iossifov I, et al. De novo gene disruptions in children on the autistic spectrum. *Neuron.* 2012; 74:285–299. [PubMed: 22542183]
35. O’Roak BJ, et al. Sporadic autism exomes reveal a highly interconnected protein network of de novo mutations. *Nature.* 2012; 485:246–250. [PubMed: 22495309]
36. Sanders SJ, et al. De novo mutations revealed by whole-exome sequencing are strongly associated with autism. *Nature.* 2012; 485:237–241. [PubMed: 22495306]
37. De Rubeis S, et al. Synaptic, transcriptional and chromatin genes disrupted in autism. *Nature.* 2014; 515:209–215. [PubMed: 25363760]
38. Cotney J, et al. The autism-associated chromatin modifier CHD8 regulates other autism risk genes during human neurodevelopment. *Nat Commun.* 2015; 6:6404. [PubMed: 25752243]

39. Sugathan A, et al. CHD8 regulates neurodevelopmental pathways associated with autism spectrum disorder in neural progenitors. *Proc Natl Acad Sci U S A*. 2014; 111:E4468–4477. [PubMed: 25294932]
40. Hawrylycz MJ, et al. An anatomically comprehensive atlas of the adult human brain transcriptome. *Nature*. 2012; 489:391–399. [PubMed: 22996553]
41. Fromer M, et al. De novo mutations in schizophrenia implicate synaptic networks. *Nature*. 2014; 506:179–184. [PubMed: 24463507]
42. Purcell SM, et al. A polygenic burden of rare disruptive mutations in schizophrenia. *Nature*. 2014; 506:185–190. [PubMed: 24463508]
43. Landrum MJ, et al. ClinVar: public archive of interpretations of clinically relevant variants. *Nucleic Acids Res*. 2016; 44:D862–868. [PubMed: 26582918]
44. Kleefstra T, et al. Loss-of-function mutations in euchromatin histone methyl transferase 1 (EHMT1) cause the 9q34 subtelomeric deletion syndrome. *Am J Hum Genet*. 2006; 79:370–377. [PubMed: 16826528]
45. Lu W, et al. NFIA haploinsufficiency is associated with a CNS malformation syndrome and urinary tract defects. *PLoS Genet*. 2007; 3:e80. [PubMed: 17530927]
46. Rosenfeld JA, et al. Small deletions of SATB2 cause some of the clinical features of the 2q33.1 microdeletion syndrome. *PLoS One*. 2009; 4:e6568. [PubMed: 19668335]
47. Talkowski ME, et al. Assessment of 2q23.1 microdeletion syndrome implicates MBD5 as a single causal locus of intellectual disability, epilepsy, and autism spectrum disorder. *Am J Hum Genet*. 2011; 89:551–563. [PubMed: 21981781]
48. Rasmussen MB, et al. Neurodevelopmental disorders associated with dosage imbalance of ZBTB20 correlate with the morbidity spectrum of ZBTB20 candidate target genes. *J Med Genet*. 2014; 51:605–613. [PubMed: 25062845]
49. DeSanto C, et al. WAC loss-of-function mutations cause a recognisable syndrome characterised by dysmorphic features, developmental delay and hypotonia and recapitulate 10p11.23 microdeletion syndrome. *J Med Genet*. 2015; 52:754–761. [PubMed: 26264232]
50. Turner TN, et al. Loss of delta-catenin function in severe autism. *Nature*. 2015; 520:51–56. [PubMed: 25807484]
51. Xia F, et al. De novo truncating mutations in AHDC1 in individuals with syndromic expressive language delay, hypotonia, and sleep apnea. *Am J Hum Genet*. 2014; 94:784–789. [PubMed: 24791903]
52. Splawski I, et al. Severe arrhythmia disorder caused by cardiac L-type calcium channel mutations. *Proc Natl Acad Sci U S A*. 2005; 102:8089–8096. discussion 8086–8088. [PubMed: 15863612]
53. Petrovski S, et al. Germline De Novo Mutations in GNB1 Cause Severe Neurodevelopmental Disability, Hypotonia, and Seizures. *Am J Hum Genet*. 2016; 98:1001–1010. [PubMed: 27108799]
54. Floris C, et al. Two patients with balanced translocations and autistic disorder: CSMD3 as a candidate gene for autism found in their common 8q23 breakpoint area. *Eur J Hum Genet*. 2008; 16:696–704. [PubMed: 18270536]
55. Cardoso C, et al. Periventricular heterotopia, mental retardation, and epilepsy associated with 5q14.3-q15 deletion. *Neurology*. 2009; 72:784–792. [PubMed: 19073947]
56. Engels H, et al. A novel microdeletion syndrome involving 5q14.3-q15: clinical and molecular cytogenetic characterization of three patients. *Eur J Hum Genet*. 2009; 17:1592–1599. [PubMed: 19471318]
57. Le Meur N, et al. MEF2C haploinsufficiency caused by either microdeletion of the 5q14.3 region or mutation is responsible for severe mental retardation with stereotypic movements, epilepsy and/or cerebral malformations. *J Med Genet*. 2010; 47:22–29. [PubMed: 19592390]
58. Zweier M, et al. Mutations in MEF2C from the 5q14.3q15 microdeletion syndrome region are a frequent cause of severe mental retardation and diminish MECP2 and CDKL5 expression. *Hum Mutat*. 2010; 31:722–733. [PubMed: 20513142]
59. Saitsu H, et al. De novo 5q14.3 translocation 121.5-kb upstream of MEF2C in a patient with severe intellectual disability and early-onset epileptic encephalopathy. *Am J Med Genet A*. 2011; 155A: 2879–2884. [PubMed: 21990267]

60. Zweier M, Rauch A. TheMEF2C-Related and 5q14.3q15 Microdeletion Syndrome. *Mol Syndromol*. 2012; 2:164–170. [PubMed: 22670137]
61. Dixon JR, et al. Topological domains in mammalian genomes identified by analysis of chromatin interactions. *Nature*. 2012; 485:376–380. [PubMed: 22495300]
62. Lupianez DG, et al. Disruptions of topological chromatin domains cause pathogenic rewiring of gene-enhancer interactions. *Cell*. 2015; 161:1012–1025. [PubMed: 25959774]
63. Lupianez DG, Spielmann M, Mundlos S. Breaking TADs: How Alterations of Chromatin Domains Result in Disease. *Trends Genet*. 2016; 32:225–237. [PubMed: 26862051]
64. Franke M, et al. Formation of new chromatin domains determines pathogenicity of genomic duplications. *Nature*. 2016
65. Mencarelli MA, et al. 14q12 Microdeletion syndrome and congenital variant of Rett syndrome. *Eur J Med Genet*. 2009; 52:148–152. [PubMed: 19303466]
66. Ellaway CJ, et al. 14q12 microdeletions excluding FOXP1 give rise to a congenital variant Rett syndrome-like phenotype. *Eur J Hum Genet*. 2013; 21:522–527. [PubMed: 22968132]
67. Takagi M, et al. A 2.0 Mb microdeletion in proximal chromosome 14q12, involving regulatory elements of FOXP1, with the coding region of FOXP1 being unaffected, results in severe developmental delay, microcephaly, and hypoplasia of the corpus callosum. *Eur J Med Genet*. 2013; 56:526–528. [PubMed: 23895774]
68. Perche O, et al. Dysregulation of FOXP1 pathway in a 14q12 microdeletion case. *Am J Med GenetA*. 2013; 161A:3072–3077.
69. Ibn-Salem J, et al. Deletions of chromosomal regulatory boundaries are associated with congenital disease. *Genome Biol*. 2014; 15:423. [PubMed: 25315429]
70. Deng Y, Gao L, Wang B, Guo X. HPOSim: an R package for phenotypic similarity measure and enrichment analysis based on the human phenotype ontology. *PLoS One*. 2015; 10:e0115692. [PubMed: 25664462]
71. Brunetti-Pierri N, et al. Duplications of FOXP1 in 14q12 are associated with developmental epilepsy, mental retardation, and severe speech impairment. *Eur J Hum Genet*. 2011; 19:102–107. [PubMed: 20736978]
72. McDermott SM, et al. *Drosophila* Syncip modulates the expression of mRNAs encoding key synaptic proteins required for morphology at the neuromuscular junction. *RNA*. 2014; 20:1593–1606. [PubMed: 25171822]
73. Warburton D. De novo balanced chromosome rearrangements and extra marker chromosomes identified at prenatal diagnosis: clinical significance and distribution of breakpoints. *Am J Hum Genet*. 1991; 49:995–1013. [PubMed: 1928105]
74. Brand H, et al. Cryptic and complex chromosomal aberrations in early-onset neuropsychiatric disorders. *Am J Hum Genet*. 2014; 95:454–461. [PubMed: 25279985]
75. Chaisson MJ, et al. Resolving the complexity of the human genome using single-molecule sequencing. *Nature*. 2015; 517:608–611. [PubMed: 25383537]
76. Huddleston J, et al. Reconstructing complex regions of genomes using long-read sequencing technology. *Genome Res*. 2014; 24:688–696. [PubMed: 24418700]
77. Lettice LA, et al. Enhancer-adoption as a mechanism of human developmental disease. *Hum Mutat*. 2011; 32:1492–1499. [PubMed: 21948517]
78. Krzywinski M, et al. Circos: an information aesthetic for comparative genomics. *Genome Res*. 2009; 19:1639–1645. [PubMed: 19541911]
79. Andersson R, et al. An atlas of active enhancers across human cell types and tissues. *Nature*. 2014; 507:455–461. [PubMed: 24670763]
80. Hanscom C, Talkowski M. Design of large-insert jumping libraries for structural variant detection using illumina sequencing. *Curr Protoc Hum Genet*. 2014; 80:7 22 21–29.
81. Higgins AW, et al. Characterization of apparently balanced chromosomal rearrangements from the developmental genome anatomy project. *Am J Hum Genet*. 2008; 82:712–722. [PubMed: 18319076]
82. Kohler S, et al. Clinical diagnostics in human genetics with semantic similarity searches in ontologies. *Am J Hum Genet*. 2009; 85:457–464. [PubMed: 19800049]

83. Brand H, et al. Paired-Duplication Signatures Mark Cryptic Inversions and Other Complex Structural Variation. *Am J Hum Genet.* 2015; 97:170–176. [PubMed: 26094575]
84. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. *Bioinformatics.* 2009; 25:1754–1760. [PubMed: 19451168]
85. Tarasov A, Vilella AJ, Cuppen E, Nijman IJ, Prins P. Sambamba: fast processing of NGS alignment formats. *Bioinformatics.* 2015; 31:2032–2034. [PubMed: 25697820]
86. North BV, Curtis D, Sham PC. A note on the calculation of empirical P values from Monte Carlo procedures. *Am J Hum Genet.* 2002; 71:439–441. [PubMed: 12111669]
87. Durand NC, et al. Juicebox Provides a Visualization System for Hi-C Contact Maps with Unlimited Zoom. *Cell Syst.* 2016; 3:99–101. [PubMed: 27467250]




Figure 1. Characterization of BCAs detected by karyotyping at nucleotide resolution
a. Genome-wide map of all BCA breakpoints identified in the cohort by whole-genome sequencing⁷⁸. One color is used per BCA to represent all rearrangement breakpoints in each subject. The scatter plot on the outside ring denotes breakpoint density per 1-Mb bin across the genome, with a blue arrow displaying the largest clustering of breakpoints at 5q14.3; **b.** Scatter plot summarizing the overall genomic imbalance associated with fully reconstructed BCAs at varying size thresholds. Curves represent the fraction of cases with final genomic imbalances greater than the corresponding size provided. Solid lines denote the final

genomic imbalances for all BCAs, and are further delineated by deletions (red) or duplications (blue). The final genomic imbalances among fully mapped BCAs is also split between cases that have been pre-screened by CMA (dashed line) versus cases without CMA data (dotted line); **c.** Sequence signatures of BCA breakpoints. Histogram representing nucleotide signatures at the junction of 662 Sanger-validated breakpoints: inserted nucleotides, blunt ends, microhomology, or longer stretches of homology.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript





Figure 2. *De novo* BCAs associated with congenital anomalies disrupt functionally relevant loci. **a.** Boxplots illustrate specific gene-set enrichments at BCA breakpoints in subjects with congenital anomalies. Each boxplot represents the expected distribution (median, first and third quartiles) based on total intersections between 100,000 sets of simulated breakpoints and a particular gene-set. Red diamonds indicate the observed intersection values. Empirical Monte-Carlo *P-values* are indicated; **b.** Venn diagram showing the detailed overlap of disrupted genes previously associated with three neurodevelopmental phenotypes in amalgamated exome and CNV studies. In black: high-confidence genes (3 or more *de novo* LoF mutations reported), in grey: low-confidence genes (two *de novo* LoF mutations). **c–e**) Diagnostic yields associated with the overall cohort and multiple subgroups of BCAs. **c.** Diagnostic yield associated with all 248 mapped BCAs from subjects with congenital or developmental anomalies; **d.** Diagnostic yields partitioned by inheritance status; **e.** Diagnostic yields associated with BCAs depleted for large pathogenic CNVs thanks to CMA pre-screen compared to BCAs that had not been pre-screened by CMA.

**Figure 3.**

Recurrent disruption of long-range regulatory interactions at the 5q14.3 locus.

a. Genome-wide distribution of BCA breakpoints in the cohort across each 1-Mb bin. P -values correspond to observed vs. expected cluster sizes after 100,000 Monte Carlo randomizations. Corrected P -values are reported. One cluster, localized to 5q14.3, achieved genome-wide significance (threshold demarcated by red line); **b.** Hi-C profile and contact domains at the 5q14.3 locus derived from human LCLs. Overlapping Hi-C data suggests that the topology of the *MEF2C*-contact domain is altered in subjects carrying BCAs¹⁷. Brain-expressed enhancers located in the region⁷⁹, loops involving *MEF2C* (yellow circles)¹⁷ and CTCF binding sites (green: forward, red: reverse) are indicated. Multiple pathogenic mechanisms converge on a similar syndrome: multi-genic deletions that encompass *MEF2C*

along with one or both TAD boundaries (n=68), *MEF2C*-intrinsic deletions (n=12) or LoF mutations, deletions that do not encompass *MEF2C* but overlap one TAD boundary (n=13), and BCA breakpoints distal to *MEF2C* (breakpoints from seven subjects reported in this study and three previously reported subjects)^{14,54,59}; **c.** Proposed model of the chromatin folding in the region defining a regulatory unit for *MEF2C*; **d.** Significantly decreased expression of *MEF2C* was observed in subjects harboring BCAs distal to *MEF2C* compared to controls. *MEF2C*-expression was measured by qRT-PCR, normalized against three endogenous genes and compared to the average *MEF2C*-expression from 16 age-matched controls (two-sided Wilcoxon rank-sum test: DGAP131, DGAP191, DGAP222: $P=0.0085$, DGAP218: $P=0.0160$). Individual expression values, median, first and third quartiles are indicated.




Figure 4. Correlations between phenotypes and genes disrupted in subjects harboring pathogenic BCAs. For each gene, the phenotypes reported in the corresponding subject were digitalized using HPO¹⁸. One tile represents the normalized count of HPO terms belonging to each organ category reported in the subject(s). Genes clustered together when sharing similarly affected organs, from which five groups can be delineated: 1- genes associated with multiple nervous system and craniofacial abnormalities (dark blue); 2- genes connected to multiple neurological phenotypes (pink); 3- genes associated with craniofacial abnormalities and a few neurological symptoms (black); 4- genes associated with skeletal and limb abnormalities, and with limited neurological involvement (green); 5- genes without neurological involvement (light blue).

Table 1

Overview of clinical phenotypes for all 273 subjects

	Affected subjects	Frequency in cohort
Gender		
Male	159	58.2%
Female	114	41.8%
Co-Segregation		
<i>De novo</i>	184	67.4%
Unknown	75	27.5%
Inherited, segregating	14	5.1%
array-CGH analyses		
Normal	139	50.9%
VUS	32	11.7%
Not Performed	102	37.4%
Abdomen defects	54	19.8%
Cardiovascular defects	41	15.0%
Eye defects	54	19.8%
Hearing defects	52	19.0%
Genitourinary defects	50	18.3%
Growth defects	64	23.4%
Head/Neck/Craniofacial defects	140	51.3%
Integument defects	50	18.3%
Limb defects	57	20.9%
Musculature defects	71	26.0%
Neurological defects	219	80.2%
Behavior disorders	51	18.7%
Developmental delay	159	58.2%
Epilepsy	51	18.7%
Hypotonia	41	15.0%
ASD/autistic features	31	11.4%
High functioning ASD	4	1.5%
Respiratory defects	30	11.0%
Skeletal defects	116	42.4%

Clinical description was converted for all 273 subjects into standardized terms using Human Phenotype Ontology (HPO)¹⁸, which allowed systematic association with broad phenotypic categories for each enrolled subject.

Table 2 Genes and loci disrupted by BCAs and likely associated with developmental disorders

Pathogenic	
Genomic imbalances at breakpoints	2q24.3 deletion (<i>SCN9A</i>); 4q34 deletion; 6q13-q14.1 deletion (<i>PHIP^a</i>); 6q14.1 deletion (<i>TBX18^b</i>); 6q22.1-22.31 deletion (<i>GATA1</i>); 10p15.3-p14 deletion (<i>GATA3</i>); 11p14.2 deletion; 12p12.1-p11.22 deletion (<i>SOX5</i> , <i>PTHLH</i>); 13q14.2 deletion; 14q12-q21.1 deletion (<i>NFKBIA</i> , <i>NKX2-1^c</i>); 18p11.32-p11.22 deletion ^d ; 19q12-q13.11 deletion; Xq25 duplication
Gene disruption	<i>AHDC1</i> ; <i>AUTS2_(x2)</i> ; <i>CAMTA1</i> ; <i>CDKL5</i> ; <i>CHD7</i> ; <i>CHD8</i> ; <i>CTNND2</i> ; <i>CUL3</i> ; <i>DYRK1A</i> ; <i>EFTUD2</i> ; <i>EHMT1</i> ; <i>FGFR1</i> ; <i>FOXP1</i> ; <i>FOXP2</i> ; <i>GRIN2B</i> ; <i>IL1RAPL1</i> ; <i>KAT6B</i> ; <i>KDM6A_(x2)</i> ; <i>MBD5_(x3)</i> ; <i>MEF2C</i> ; <i>MTAP</i> ; <i>MYT1L_(x2)</i> ; <i>MYO6^e</i> ; <i>NALCN</i> ; <i>NFIA</i> ; <i>NFIX</i> ; <i>NODAL</i> ; <i>NOTCH2</i> ; <i>NR2F1</i> ; <i>NR5A1</i> ; <i>NRXN1</i> ; <i>NSD1</i> ; <i>PAK3</i> ; <i>PDE10A</i> ; <i>PHF21A_(x2)</i> ^d ; <i>PHIP^e</i> ; <i>SATB2</i> ; <i>SCN1A</i> ; <i>SMS</i> ; <i>SNRPN-SNURF_(x3)</i> ; <i>SOX5_(x2)</i> ; <i>SPAST</i> ; <i>TCF12</i> ; <i>TCF4</i> ; <i>WAC</i> ; <i>ZBTB20_(x2)</i>
Likely Pathogenic	
Genomic imbalances at breakpoints	2p21-p13.3 duplication (<i>NRXN1</i>)
Gene disruption	<i>ARIHI</i> ; <i>BBX</i> ; <i>CACNA2D3</i> ; <i>CACNA1C</i> ; <i>CADPS2</i> ; <i>CDK6_(x2)</i> ; <i>CELSR1</i> ; <i>EP400^f</i> ; <i>GNB1</i> ; <i>GRM1^h</i> ; <i>KCND2</i> ; <i>MDN1</i> ; <i>NFIB</i> ; <i>NPAS3_(x4)</i> ; <i>c-i</i> ; <i>NRXN3</i> ; <i>PRPF40A</i> ; <i>PSD3</i> ; <i>PTPRZ1_(x3)</i> ^{a,f} ; <i>ROBO2</i> ; <i>SHROOM4^g</i> ; <i>SPTBN1</i> ; <i>SYNCRIP_(x2)</i> ^{b,i} ; <i>STXBP5^h</i> ; <i>UPF2</i> ; 11p15 region
Positional effect	<i>FOXYG1_(x4)</i> ⁱ ; <i>MEF2C_(x7)</i> ; <i>PITX2</i> ; <i>SATB2_(x3)</i> ^j ; <i>SLC2A1</i> ; <i>SOX9</i> ; <i>SRCAP</i>

Details on BCA interpretation are provided in **Methods** and Supplementary Table 7. Genes that have been associated to dominant developmental disorders and encompassed by genomic imbalances at breakpoints are indicated in brackets; lower-scripts indicate when a gene was disrupted by a BCA in multiple subjects; upper-scripts report subjects with a BCA disrupting multiple genes/loci that may each contribute to their developmental phenotype and to distinct clinical features;

^a : Subject DGAP133;

^b : Subject DGAP317,

^c : subject DGAP002,

^d : subject DGAP316,

^e : subject NIJ2,

^f : subject DGAP168,

^g : subject DGAP172,

^h : DGPA196;

ⁱ : DGAP246;

^j : DGAP237.